Browsing Clinical Studies by author "Harrington, Kevin"
Now showing items 1-20 of 20
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
Nutting, C; Morden, J; Bernstein, D; Beasley, M; Cosgrove, V; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
Clinical development of new drug-radiotherapy combinations.
Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; et al. (NATURE PUBLISHING GROUP, 2016-10-01)In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ... -
Combining Molecularly Targeted Agents: Is More Always Better?
Sundar, R; Valeri, N; Harrington, KJ; Yap, TA (AMER ASSOC CANCER RESEARCH, 2017-03-01)The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming ... -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
Nutting, C; Morden, J; Beasley, M; Bhide, S; Emson, M; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar, I; Rooney, K; Roe, JWG; Patterson, JM; Bernstein, D; et al. (BMC, 2016-10-06)BACKGROUND: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of ... -
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Nutting, CM; Griffin, CL; Sanghera, P; Foran, B; Beasley, M; et al. (ELSEVIER SCI LTD, 2021-08-01)BACKGROUND: Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-03)Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ... -
Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).
Harrington, K; Hall, E; Hawkins, M; Henry, A; MacKay, R; et al. (2017-11) -
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Dillon, MT; Boylan, Z; Smith, D; Guevara, J; Mohammed, K; et al. (ELSEVIER IRELAND LTD, 2018-08-01)PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and ... -
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.
Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; et al. (2018-04) -
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol.
Kong, A; Good, J; Kirkham, A; Savage, J; Mant, R; et al. (BMJ PUBLISHING GROUP, 2020-03-16)INTRODUCTION: Patients with head and neck squamous cell carcinoma with locally advanced disease often require multimodality treatment with surgery, radiotherapy and/or chemotherapy. Adjuvant radiotherapy with concurrent ... -
Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah, AB; Gulliford, SL; Morden, J; Newbold, KL; Bhide, SA; et al. (ELSEVIER SCIENCE LONDON, 2016-09-01)AIMS: To establish whether there is a difference in recovery of salivary function with bilateral superficial lobe parotid-sparing intensity-modulated radiotherapy (BSLPS-IMRT) versus contralateral parotid-sparing IMRT ... -
Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer
Kong, A; Kirkham, AJ; Savage, JS; Mant, R; Lax, S; et al. (Springer Science and Business Media LLC, 2024-01-29)<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates the activity of various ... -
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
Nutting, CM; Morden, JP; Beasley, M; Bhide, S; Cook, A; et al. (ELSEVIER SCI LTD, 2018-11-01)PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the ... -
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
Wilkins, A; Furness, A; Corbett, RW; Bloomfield, A; Porta, N; et al. (NATURE PUBLISHING GROUP, 2015-11-03)BACKGROUND: The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups. It was largely derived using clinical data from patients ... -
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.
de Mol van Otterloo, SR; Christodouleas, JP; Blezer, ELA; Akhiat, H; Brown, K; et al. (FRONTIERS MEDIA SA, 2020-09-07)Purpose: MR-guided Radiation Therapy (MRgRT) allows for high-precision radiotherapy under real-time MR visualization. This enables margin reduction and subsequent dose escalation which may lead to higher tumor control and ...